Efficacy, safety and bioequivalence of the human‐derived B‐domain‐deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients

INTRODUCTION: Current treatment of severe haemophilia A includes prophylaxis with factor VIII (FVIII) replacement. The supply of plasma‐derived FVIII is short in China. PURPOSE: To evaluate the efficacy and safety of a new B‐domain deleted (BDD) recombinant FVIII (TQG202) produced by human‐derived c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Yaming, Jin, Chenghao, Liu, Wei, Zhou, Hu, Wang, Zhen, Zhou, Rongfu, Lou, Shifeng, Zhao, Xielan, Chen, Fangping, Cheng, Peng, Sun, Zimin, Jia, Haifei, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805152/
https://www.ncbi.nlm.nih.gov/pubmed/35996199
http://dx.doi.org/10.1111/hae.14652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805152/
https://www.ncbi.nlm.nih.gov/pubmed/35996199
http://dx.doi.org/10.1111/hae.14652

Ejemplares similares